Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer

Julia A. Shevchenko, Alexander A. Khristin, Vasily V. Kurilin, Maria S. Kuznetsova, Darya D. Blinova, Natalya M. Starostina, Sergey V. Sidorov, Sergey V. Sennikov

Результат исследования: Научные публикации в периодических изданияхстатья

Выдержка

Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.

Язык оригиналаанглийский
Страницы (с-по)671-680
Число страниц10
ЖурналOncology Reports
Том43
Номер выпуска2
DOI
СостояниеОпубликовано - фев 2020

Отпечаток

Dendritic Cells
Breast Neoplasms
Neoplasm Metastasis
Immunotherapy
Immunity
Therapeutics
Recurrence
Interleukin-18
Autoantigens
Residual Neoplasm
Regulatory T-Lymphocytes
Interleukin-12
Immunosuppressive Agents
Disease Progression
Neoplasms
Lymphocytes
Pathology
T-Lymphocytes
Antigens
Population

Цитировать

Shevchenko, J. A., Khristin, A. A., Kurilin, V. V., Kuznetsova, M. S., Blinova, D. D., Starostina, N. M., ... Sennikov, S. V. (2020). Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer. Oncology Reports, 43(2), 671-680. https://doi.org/10.3892/or.2019.7435
Shevchenko, Julia A. ; Khristin, Alexander A. ; Kurilin, Vasily V. ; Kuznetsova, Maria S. ; Blinova, Darya D. ; Starostina, Natalya M. ; Sidorov, Sergey V. ; Sennikov, Sergey V. / Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer. В: Oncology Reports. 2020 ; Том 43, № 2. стр. 671-680.
@article{611e0b23794142d9a50cdda90d72b9c1,
title = "Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer",
abstract = "Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.",
keywords = "Breast cancer, Cancer immunotherapy, Cytotoxic T lymphocytes, Cytotoxicity, Dendritic cells, T-helper cell polarization",
author = "Shevchenko, {Julia A.} and Khristin, {Alexander A.} and Kurilin, {Vasily V.} and Kuznetsova, {Maria S.} and Blinova, {Darya D.} and Starostina, {Natalya M.} and Sidorov, {Sergey V.} and Sennikov, {Sergey V.}",
year = "2020",
month = "2",
doi = "10.3892/or.2019.7435",
language = "English",
volume = "43",
pages = "671--680",
journal = "Oncology Reports",
issn = "1021-335X",
number = "2",

}

Shevchenko, JA, Khristin, AA, Kurilin, VV, Kuznetsova, MS, Blinova, DD, Starostina, NM, Sidorov, SV & Sennikov, SV 2020, 'Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer', Oncology Reports, том. 43, № 2, стр. 671-680. https://doi.org/10.3892/or.2019.7435

Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer. / Shevchenko, Julia A.; Khristin, Alexander A.; Kurilin, Vasily V.; Kuznetsova, Maria S.; Blinova, Darya D.; Starostina, Natalya M.; Sidorov, Sergey V.; Sennikov, Sergey V.

В: Oncology Reports, Том 43, № 2, 02.2020, стр. 671-680.

Результат исследования: Научные публикации в периодических изданияхстатья

TY - JOUR

T1 - Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer

AU - Shevchenko, Julia A.

AU - Khristin, Alexander A.

AU - Kurilin, Vasily V.

AU - Kuznetsova, Maria S.

AU - Blinova, Darya D.

AU - Starostina, Natalya M.

AU - Sidorov, Sergey V.

AU - Sennikov, Sergey V.

PY - 2020/2

Y1 - 2020/2

N2 - Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.

AB - Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL-12 and IL-18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease-free period was performed for 3 years after surgery. The use of antigen-loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.

KW - Breast cancer

KW - Cancer immunotherapy

KW - Cytotoxic T lymphocytes

KW - Cytotoxicity

KW - Dendritic cells

KW - T-helper cell polarization

UR - http://www.scopus.com/inward/record.url?scp=85077732371&partnerID=8YFLogxK

U2 - 10.3892/or.2019.7435

DO - 10.3892/or.2019.7435

M3 - Article

C2 - 31894312

AN - SCOPUS:85077732371

VL - 43

SP - 671

EP - 680

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -

Shevchenko JA, Khristin AA, Kurilin VV, Kuznetsova MS, Blinova DD, Starostina NM и соавт. Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer. Oncology Reports. 2020 Февр.;43(2):671-680. https://doi.org/10.3892/or.2019.7435